https://www.cnn.com/2026/10/13/health/glp-1-drugs-anti-aging

Late-life semaglutide treatment slows ageing and extends lifespan in female mice

https://www.nature.com/articles/s41586-026-10940-7

Weight-loss jabs may slow biological ageing, landmark new study suggests

GLP-1 drugs are best known for treating diabetes and obesity, but could they also help to slow down how we age?

https://www.sciencefocus.com/the-human-body/glp1-drugs-slow-biological-ageing

+++++++++

Great marketing for the pharmaceutical companies selling this drug! Color me skeptical that this is not mostly from just losing weight.

 I get the massive benefits to overweight people that cant lose weight from conventional strategies. Unquestionably these people have tremendous benefits vs any risks.

However, I note that they don't mention things like this:

AI Overview

Yes, GLP-1 receptor agonists can lead to a decrease in lean body mass and muscle tissue, though this is a normal part of weight loss rather than a unique side effect of the drugs themselves. [1]Key Facts About GLP-1s and Muscle Loss

• Proportion of Lean Mass Loss: Studies show that roughly 15% to 40% (and in some estimates up to 25%–50%) of the total weight lost while taking GLP-1 medications—such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)—comes from lean tissue (which includes muscle, water, and organs), while the remaining 60% to 85% comes from fat. [1, 2, 3, 4]
• Not Unique to GLP-1s: Any form of significant or rapid weight loss—whether through traditional calorie restriction, dieting, or bariatric surgery—results in a combination of fat and lean mass loss. [1, 2]
• Lean Mass vs. True Muscle: Much of the measured "lean mass" reduction reflects water weight, changes in liver volume, and reduced mechanical load on the body rather than severe muscle destruction. [1, 2]
• Higher-Risk Groups: Older adults, sedentary individuals, people with existing frailty, or those who experience severe appetite suppression and under-eat protein face a higher risk of problematic muscle weakness or sarcopenia.

+++++++++++++

Muscle loss and GLP-1R agonists use

https://pmc.ncbi.nlm.nih.gov/articles/PMC12957034/

Conclusions

Skeletal muscle wasting is a frequent and clinically significant complication in patients with T2D and obesity, which is exacerbated by chronic inflammation, insulin resistance and metabolic dysregulation. While highly effective for weight loss and cardiometabolic protection, GLP-1RAs may contribute to lean mass reduction, highlighting the importance of monitoring muscle health during therapy. Integrated strategies combining adequate protein intake, resistance exercise, and, where appropriate, emerging pharmacological interventions can help preserve or restore muscle mass. Further research, including long-term evaluation of sarcopenia in GLP-1RAs trials, development of standardized monitoring protocols and investigation of combined nutritional, exercise and pharmacologic strategies, is needed in order to prevent muscle loss while maximizing metabolic benefits under GLP-1RAs treatment.

+++++++++++

This is a HUGE deal but the media coverage of this breaking news on a potential fountain of youth does not mention it!